Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Phase 2 Interventional

Exisulind Prior to Radical Prostatectomy

NCT00166478
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Exisulind Therapy
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT03338790
View directory record Official record
Conditions
Prostate Cancer
Interventions
nivolumab, docetaxel, enzalutamide, rucaparib, prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Daphne, Alabama • Rancho Mirage, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result

NCT01024959
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PCA3 Assay
Other
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
40 Years and older · Male only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 26, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

NCT04157088
View directory record Official record
Conditions
Prostatic Cancer, Castration-Resistant
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Portland, Maine • Voorhees Township, New Jersey • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Conservative Treatment of Postprostatectomy Incontinence

NCT00212264
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Behavioral Therapy, Pelvic Floor Electrical Stimulation, Biofeedback, No Treatment
Behavioral · Device · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Male only
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 26, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

NCT04363164
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Not applicable Interventional Results available

Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy

NCT04098809
View directory record Official record
Conditions
Prostate Cancer
Interventions
16 French urinary catheter, 20 French urinary catheter
Device
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Sulforaphane on Normal Prostate Tissue

NCT00946309
View directory record Official record
Conditions
Prostate Cancer
Interventions
High Sulforaphane Extract (Broccoli Sprout Extract), Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 26, 2026, 4:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer

NCT01983709
View directory record Official record
Conditions
Prostate Cancer
Interventions
Allogeneic Human Mesenchymal Stem Cells
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 26, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

NCT03886493
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dupilumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 26, 2026, 4:47 AM EDT
Completed No phase listed Observational

Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

NCT00035217
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

NCT02001571
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 26, 2026, 4:47 AM EDT
Terminated Not applicable Interventional

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

NCT02024685
View directory record Official record
Conditions
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions
Personalized Treatment Recommendations, Standard patient-physician counseling interaction
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery

NCT00792961
View directory record Official record
Conditions
Prostate Cancer
Interventions
Endomicroscopy
Device
Lead sponsor
Peter Delaney
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 26, 2026, 4:47 AM EDT
Not yet recruiting Not applicable Interventional

SURPASS: Stereotactic Ultra-hypofractionated Radiotherapy for Post-prostatectomy Patients: Adaptive Salvage SBRT

NCT07888283
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Adaptive stereotactic body radiotherapy (SBRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 4:47 AM EDT
Recruiting Early Phase 1 Interventional

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

NCT05045066
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Interventions
Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
Dietary Supplement · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

NCT01517802
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Interventions
Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
10
States / cities
Aurora, Colorado • Marrero, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Transluminal Flexible Endoscopic Procedure in Foregut and Urologic Surgery

NCT00484783
View directory record Official record
Conditions
Gastric Foreign Body, Nos, Disorder of Abdomen (Disorder), Foreign Body in Esophagus, Prostatic Diseases, Disease of Small Intestine
Interventions
Natural Orifice Transluminal Endoscopic Surgery (NOTES), Natural Orifice Translumenal Endoscopic Surgery (NOTES)
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 26, 2026, 4:47 AM EDT
Withdrawn No phase listed Observational

Effect of Lap-Band Induced Weight Loss on Serum PSA Levels

NCT00562341
View directory record Official record
Conditions
Obesity, Prostate Cancer
Interventions
Bariatric Surgery
Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
20 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 26, 2026, 4:47 AM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Ablative Radiation Therapy for Prostate Cancer

NCT05668351
View directory record Official record
Conditions
Prostate Cancer
Interventions
SUPR-SABR treatment
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 26, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

BKM120 in Metastatic Castration-resistant Prostate Cancer

NCT01385293
View directory record Official record
Conditions
Prostate Cancer, Metastatic (Spread to Other Areas of the Body)
Interventions
BKM120
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 26, 2026, 4:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 26, 2026, 4:47 AM EDT